Biosidus étend sa capacité de production de médicaments biologiques et renforce ses capacités d'approvisionnement mondiales en agalsidase bêta

agalsidase betaPositive

AI Analysis

Summary

Biosidus announced the operationalization of a new bioreactor facility to expand its biologic drug manufacturing capacity and strengthen global supply capabilities for agalsidase beta.

Importance:3/10

Sentiment:

0.60

capacity expansionmanufacturingbiologicsbiosimilarsagalsidase betasupply chain

Read the original article

Published by PR Newswire Biotech on August 27, 2026 10:26 AM

Read Original